Areteia Therapeutics

📍 Research Triangle Park, United States🗓 Founded 2022👥 35 employees💰 Last funded Jan 2024
Biotechnology Research🌐 areteiatx.com
Website LinkedIn
Areteia Therapeutics is a new biotechnology company committed to putting asthma patients in better control of their disease—and back in control of their lives—with the first potential oral drug for eosinophilic asthma.
3
Total investors
3
Early stage
0
Mid stage
0
Late stage
2022
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
3
Investor activity2022–2024 · investors recorded per year
2022220241
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Areteia Therapeutics?
Areteia Therapeutics has 3 investors on record on gritt.io, including 3 early-stage backers.
When did Areteia Therapeutics last raise funding?
The most recent investment in Areteia Therapeutics recorded on gritt.io was in January 2024.
When was Areteia Therapeutics founded?
Areteia Therapeutics was founded in 2022.
What industry is Areteia Therapeutics in?
Areteia Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Areteia Therapeutics based?
Areteia Therapeutics is headquartered in Research Triangle Park, United States.